CERS

Cerus Corp. is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety, headquartered in Concord, California. The company's technology platform uses a proprietary pathogen reduction system to inactivate viruses, bacteria, and parasites in blood components including platelets, plasma, and red blood cells before transfusion. INTERCEPT technology helps reduce the risk of transfusion-transmitted infections while maintaining the therapeutic quality of blood products. Cerus markets its systems to blood centers, hospitals, and national health services globally. The company has received regulatory approvals and CE Mark certification in multiple international markets. INTERCEPT addresses an important clinical need by providing an additional layer of safety for blood transfusions beyond traditional screening methods, particularly relevant for emerging infectious disease threats.